Gamida Cell Stock News

Gamida Cell Ltd. (NASDAQ:GMDA) Equities researchers at Piper Sandler upped their FY2021 EPS estimates for Gamida Cell in a research note issued to investors on Monday, November 15th. Piper Sandler analyst E. Tenthoff now forecasts that the company will earn ($1.45) per share for the year, up from their prior estimate of ($1.51). Piper []

Gamida Cell (NASDAQ:GMDA) had its target price lowered by Oppenheimer from $17.00 to $15.00 in a report issued on Tuesday morning, The Fly reports. The brokerage currently has an outperform rating on the stock. Several other analysts have also issued reports on the company. Alliance Global Partners started coverage on Gamida Cell in a research []

Gamida Cell (NASDAQ:GMDA) announced its quarterly earnings data on Monday. The company reported ($0.33) earnings per share for the quarter, beating analysts consensus estimates of ($0.48) by $0.15, Fidelity Earnings reports. During the same quarter in the prior year, the company posted ($0.30) EPS. Shares of NASDAQ:GMDA traded down $0.04 on Tuesday, hitting $3.36. The []

Gamida Cell (NASDAQ:GMDA) had its target price lowered by stock analysts at Oppenheimer from $17.00 to $15.00 in a report issued on Tuesday, The Fly reports. The firm currently has an outperform rating on the stock. Oppenheimers target price indicates a potential upside of 341.18% from the companys current price. A number of other equities []

Gamida Cell Ltd (GMDA) CEO Julian Adams on Q3 2021 Results - Earnings Call Transcript

Gamida Cell (GMDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Gamida Cell (GMDA) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wa

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today reported financial results for the quarter en

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q1 2021 Results - Earnings Call Transcript

ARR, GMDA, ISEE, LMB, and LIQT have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2021

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious hematologic diseases, today announced the results of a Phase

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today reported financial results for

GMDA addressed its cash issues, but its approval got a little delayed. That was because the FDA raised manufacturing concerns.

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for blood cancers and serious blood diseases, today announced that the company will host a